My Malignant Melanoma

Seanty's experiences with Metastatic Malignant Melanoma. Part of Email us direct at

Wednesday, 23 September 2009



Another snappy blog title...There's a new trial of the promising drug formerly known as PLX4032 or RG7204, now known as RO5185426, as Hoffmann-Roche have a collaboration agreement with the original developer (Plexxikon)

There is a phase 2 trial just started, details here. It is encouraging that this is a phase 2 trial, but they haven't published the results of the previous Phase 2 trial yet.

It's looking reasonably hopeful, as I reported back in June., and there are a couple of people on the melanoma board hoping to go on the trial.

New results for the Phase 1 extension trial are more hopeful still than the initial phase 1 trial I reported on earlier. 70% response rate (compared with about 15% for the standard treatment), one complete response (cure), and an approximate average of 30% tumour shrinkage. Other treatments have looked good at this stage, so let's not get over-excited, but looking good so far.

When viewing the response rate, it should be borne in mind that if your tumours do not have a mutation (
BRAFV600E ) which is present in 50% of melanomas, you won't get the drug, so it is only perhaps twice as good as the standard treatment in terms of response rates. The manufacturer are developing a test kit for the mutation alongside the drug to screen for people it might help.

Labels: , ,

Comments: Post a Comment

Subscribe to Post Comments [Atom]

<< Home


August 2008   September 2008   October 2008   November 2008   December 2008   January 2009   February 2009   April 2009   May 2009   June 2009   July 2009   August 2009   September 2009   October 2009   November 2009   December 2009   January 2010   February 2010   March 2010   April 2010   May 2010   June 2010   July 2010   August 2010   September 2010   October 2010   November 2010   December 2010   February 2011   March 2011   April 2011   May 2011   June 2011   July 2011   August 2011   September 2011   October 2011   November 2011   December 2011   January 2012   February 2012   March 2012   April 2012   May 2012   June 2012   July 2012   September 2012   November 2012   December 2012   January 2013   May 2013   June 2013   July 2013   August 2013   September 2013   October 2013   December 2013   July 2014   May 2015   July 2015  

This page is powered by Blogger. Isn't yours?

Subscribe to Posts [Atom]